Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-101.74	-108.18	-58.24	-51.97	-14.1
Depreciation & Amortization	6.02	4.03	1.97	1.63	1.47
Share-Based Compensation	19.08	14.23	7.83	1.76	1.69
Other Operating Activities	-41.34	-19.16	-11.09	118.66	-13.88
Operating Cash Flow	-117.98	-109.08	-59.53	70.07	-24.8
Capital Expenditures	-1.53	-7.69	-1.84	-1.11	-1.82
Change in Investments	42.95	34.09	-181.6	-144.32	2.67
Other Investing Activities	-	-	-	-0.04	-
Investing Cash Flow	41.43	26.4	-183.43	-145.47	0.85
Share Issuance / Repurchase	81.96	1.62	327.34	0.04	0
Other Financing Activities	0.45	-0.01	29.99	80.84	11
Financing Cash Flow	82.41	1.62	357.33	80.88	11
Net Cash Flow	5.85	-81.07	114.36	5.49	-12.96
Free Cash Flow	-119.51	-116.77	-61.36	68.97	-26.62
Free Cash Flow Margin	-327.18%	-469.72%	-165.66%	900.84%	-108.00%
Free Cash Flow Per Share	-1.26	-1.33	-0.99	2.16	-2.96

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).